Quantcast
Home > Quotes > BIOC

Biocept, Inc. Common Stock (BIOC) Quote & Summary Data

BIOC 
$0.875
*  
0.037
4.42%
Get BIOC Alerts
*Delayed - data as of Dec. 12, 2018 9:42 ET  -  Find a broker to begin trading BIOC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    BIOC Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.875 / $ 0.92
1 Year Target
5.125
Today's High / Low
$ 0.95 / $ 0.84
Share Volume
13,624
50 Day Avg. Daily Volume
209,283
Previous Close
$ 0.838
52 Week High / Low
$ 24.6002 / $ 0.801
Market Cap
3,553,750
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.17

Intraday Chart

Shares Traded

Share Volume:
13,624
50 Day Avg. Daily Volume:
209,283

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -13.83

Trading Range

The current last sale of $0.875 is 9.24% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.95 $ 24.6002
 Low: $ 0.84 $ 0.801

Company Description (as filed with the SEC)

We are an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or "liquid biopsy." Our current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. Our assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient's disease when compared with tissue biopsy and radiographic imaging.  ... More ...  


Risk Grade

Where does BIOC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.84
Open Date:
Dec. 12, 2018
Close Price:
$ 0.838
Close Date:
Dec. 11, 2018

Consensus Recommendation

Analyst Info